Opioid-Free Versus Opioid-Based Sedation for Endoscopic Procedures
Evaluation of an Opioid-Free Approach in Sedation Method Selection in Endoscopy Units: A Prospective Randomized Observational Double-Blind Comparison of Dexmedetomidine (Opioid-Free) and Remifentanil-Dexmedetomidine (Opioid-Based) Combination
This study will compare two different sedation approaches used during gastroscopy, colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). One group will receive dexmedetomidine alone (opioid-free sedation), while the other group will receive dexmedetomidine combined with remifentanil (opioid-based sedation).
The purpose of the study is to determine whether an opioid-free sedation approach can reduce opioid-related adverse symptoms, such as nausea, vomiting, dizziness, drowsiness, dry mouth, headache, and fatigue. The study will also evaluate quality of recovery, patient and healthcare staff satisfaction, hemodynamic effects, complications, and time to discharge after the procedure.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Safe and comfortable sedation is essential for endoscopic procedures performed outside the operating room. Various sedation strategies have been developed to improve patient safety, procedural conditions, and recovery profiles. Opioids are commonly used as part of sedation regimens; however, opioid administration may be associated with adverse symptoms such as nausea, vomiting, dizziness, drowsiness, difficulty concentrating, fatigue, pruritus, dry mouth, and headache.
This prospective randomized double-blind study will compare dexmedetomidine alone (opioid-free approach) with a combination of dexmedetomidine and remifentanil (opioid-based approach) for sedation during gastroscopy, colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). Eighty ASA physical status I-III patients aged 18-80 years will be enrolled at a single center.
Participants will be randomly assigned to one of two study groups using a computer-generated randomization sequence. Study medications will be prepared by an independent anesthesiologist to maintain blinding. In both groups, dexmedetomidine infusion will be administered. The comparison group will additionally receive remifentanil infusion according to the study protocol.
The primary objective is to determine whether the opioid-free approach reduces the incidence of opioid-related adverse symptoms. Secondary objectives include evaluation of postoperative quality of recovery using the QoR-15 questionnaire and assessment of patient, surgeon, and recovery nurse satisfaction. Additional outcomes include hemodynamic parameters, sedation scores, pain scores, rescue analgesic requirements, discharge time, post-anesthesia care unit requirements, and procedure- or anesthesia-related complications.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Tuğba Yücel Yenice, MD
- Telefonní číslo: +90 212 414 71 71
- E-mail: tugbayucel09@gmail.com
Studijní záloha kontaktů
- Jméno: Sevim Bahar Bedirhan, MD
- Telefonní číslo: +90 212 414 71 71
- E-mail: sbbedirhan@gmail.com
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age 18 to 85 years
- ASA physical status I-III
- Scheduled for ERCP, gastroscopy, or colonoscopy
Exclusion Criteria:
- Refusal to participate in the study
- Inability to communicate
- Alcohol or substance abuse
- Neuropsychiatric disease
- Severe respiratory failure
- Severe heart failure
- Pregnancy
- Body mass index (BMI) >30 kg/m²
- Hearing impairment
- History of allergy to study medications
- Requirement for orotracheal intubation or general anesthesia
- Procedures lasting less than 20 minutes
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Dexmedetomidine (Opioid-Free)
Participants will receive dexmedetomidine infusion for procedural sedation.
Dexmedetomidine infusion will be initiated at 0.7 mcg/kg/h.
Five minutes later, a placebo infusion (100 mL isotonic saline) will be started.
Sedation will be induced with propofol 1.5 mg/kg IV bolus and maintained according to the study protocol.
|
Dexmedetomidine 200 mcg diluted in 100 mL isotonic saline and administered according to the study protocol.
|
|
Aktivní komparátor: Remifentanil + Dexmedetomidine
Participants will receive dexmedetomidine infusion at 0.7 mcg/kg/h.
Five minutes later, remifentanil infusion will be initiated at 0.01-0.03
mcg/kg/min.
Sedation will be induced with propofol 1.5 mg/kg IV bolus and maintained according to the study protocol.
|
Dexmedetomidine 200 mcg diluted in 100 mL isotonic saline and administered according to the study protocol.
Remifentanil 5 mg diluted in 100 mL isotonic saline and administered according to the study protocol.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Opioid-Related Adverse Symptoms
Časové okno: Perioperative/Periprocedural: from procedure start through recovery room discharge, approximately 2-4 hours
|
Incidence of opioid-related adverse symptoms including nausea, vomiting, difficulty concentrating, difficulty staying awake, dizziness, sleepiness, general fatigue or weakness, pruritus, dry mouth, and headache.
The occurrence of one or more symptoms will be recorded and compared between the opioid-free and opioid-based sedation groups.
|
Perioperative/Periprocedural: from procedure start through recovery room discharge, approximately 2-4 hours
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Quality of Recovery (QoR-15) Score
Časové okno: Baseline (before the procedure) and within 2 hours after the procedure, before discharge from the recovery area
|
Postprocedural quality of recovery assessed using the QoR-15 questionnaire.
The QoR-15 is a 15-item instrument evaluating five dimensions: physical comfort (5 items), emotional state (4 items), physical independence (2 items), psychological support (2 items), and pain (2 items).
Each item is scored 0-10 on a Likert scale; total score ranges from 0 (worst) to 150 (best quality of recovery).
Administered to all patients before the procedure (baseline) and after the procedure before discharge.
|
Baseline (before the procedure) and within 2 hours after the procedure, before discharge from the recovery area
|
|
Patient Satisfaction Score
Časové okno: Within 1 hour after the procedure, before discharge from the recovery area
|
Patient satisfaction assessed using a verbal rating scale from 1 to 10 (1: not satisfied at all, 10: very satisfied).
Administered once after the procedure before discharge from the recovery area.
|
Within 1 hour after the procedure, before discharge from the recovery area
|
|
Surgeon Satisfaction Score
Časové okno: Immediately after the procedure
|
Surgeon satisfaction with procedural conditions assessed using a verbal rating scale from 1 to 10 (1: not satisfied at all, 10: very satisfied).
Assessed immediately after the procedure.
|
Immediately after the procedure
|
|
Recovery Nurse Satisfaction Score
Časové okno: During the recovery period, before discharge
|
Recovery nurse satisfaction assessed using a verbal rating scale from 1 to 10 (1: not satisfied at all, 10: very satisfied).
Assessed during the recovery period before discharge.
|
During the recovery period, before discharge
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pain and Analgesic Outcomes
Časové okno: During the recovery period before discharge
|
Postprocedural pain assessed using the Visual Analog Scale (VAS; 0-10).
Target VAS <4.
Rescue analgesia administered as IV paracetamol 1g; tramadol 50 mg IV if insufficient.
Total rescue analgesic consumption recorded.
|
During the recovery period before discharge
|
|
Post-Anesthesia Care Unit (PACU) Requirement
Časové okno: Immediately after the procedure
|
Need for post-anesthesia care unit (PACU) admission following the procedure.
Discharge from the recovery unit will be based on the Modified Aldrete Score.
The Modified Aldrete Score ranges from 0 to 10, with higher scores indicating better recovery status.
Patients with a score of ≥9 will be considered eligible for discharge from the recovery unit.
|
Immediately after the procedure
|
|
Heart Rate
Časové okno: Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
Heart rate measured in beats per minute (bpm) at 6 standardized time points: (1) on arrival to the procedure room, (2) immediately after induction, (3) 3 minutes after procedure start, (4) 15 minutes after procedure start, (5) at the end of the procedure, (6) on arrival to the recovery room.
|
Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
|
Mean Arterial Pressure (MAP)
Časové okno: Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
Mean arterial pressure measured in millimeters of mercury (mmHg) at 6 standardized time points: (1) on arrival to the procedure room, (2) immediately after induction, (3) 3 minutes after procedure start, (4) 15 minutes after procedure start, (5) at the end of the procedure, (6) on arrival to the recovery room.
|
Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
|
Oxygen Saturation (SpO2)
Časové okno: Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
Peripheral oxygen saturation measured as percentage (%) at 6 standardized time points: (1) on arrival to the procedure room, (2) immediately after induction, (3) 3 minutes after procedure start, (4) 15 minutes after procedure start, (5) at the end of the procedure, (6) on arrival to the recovery room.
|
Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
|
Ramsay Sedation Scale Score
Časové okno: Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
Sedation depth assessed using the Ramsay Sedation Scale at 6 standardized time points: (1) on arrival to the procedure room, (2) immediately after induction, (3) 3 minutes after procedure start, (4) 15 minutes after procedure start, (5) at the end of the procedure, (6) on arrival to the recovery room. Ramsay Sedation Scale (RSS; ranging from 1 to 6, where 1 = anxious/agitated/restless and 6 = no response to stimulus; higher scores indicate deeper sedation) |
Perioperative/Periprocedural, at 6 predefined time points over approximately 1-3 hours
|
Spolupracovníci a vyšetřovatelé
Publikace a užitečné odkazy
Obecné publikace
- Yu JM, Tao QY, He Y, Liu D, Niu JY, Zhang Y. Opioid-Free Anesthesia for Pain Relief After Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial. J Pain Res. 2023 Oct 30;16:3625-3632. doi: 10.2147/JPR.S432601. eCollection 2023.
- Hao C, Xu H, Du J, Zhang T, Zhang X, Zhao Z, Luan H. Impact of Opioid-Free Anesthesia on Postoperative Quality of Recovery in Patients After Laparoscopic Cholecystectomy-A Randomized Controlled Trial. Drug Des Devel Ther. 2023 Nov 28;17:3539-3547. doi: 10.2147/DDDT.S439674. eCollection 2023.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2024-KAEK-31 (Sisli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .